Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**OMP-GEL 02** is an Oxford Medical Products preclinical peptide combination product using the company's OMP GEL hydrogel drug-delivery technology. The program is listed as actively available for partnering. Publicly available pipeline information does not disclose the constituent peptide active ingredients, biological targets, intended disease indication, administration route, or a target-specific mechanism of action. Oxford Medical Products describes its OMP GEL technology as a gastroretentive hydrogel platform intended to retain a drug product in the stomach and enable controlled elution to the proximal gastrointestinal tract.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OMP-GEL 02.